Several major studies now suggest that frequent use of sleeping pills is associated with a meaningfully higher risk of developing dementia, particularly among older adults. A 2023 study from UCSF found that white older adults who took sleep medications “often” or “almost always” had a 79% higher risk of dementia compared to those who rarely or never used them. A nationally representative study published in 2021 found sleep medication use linked to a 48% greater risk of dementia overall. And research published in The Lancet in October 2025 estimated that eliminating sleep medication use among older adults could reduce cognitive impairment by 2.1% and add 1.7 million life-years across the U.S.
population. These findings do not mean that anyone who has ever taken a sleeping pill is on a path toward cognitive decline. Occasional use has not been linked to increased dementia risk in any of the major studies. But the pattern that emerges from the research is consistent enough to warrant serious attention, especially for people who rely on these medications nightly for months or years. This article breaks down the specific studies, explains a newly discovered mechanism by which sleep drugs may impair the brain’s ability to clean itself, examines who is most at risk, and looks at safer alternatives like cognitive behavioral therapy for insomnia.
Table of Contents
- What Do Studies Say About Sleeping Pills and Dementia Risk?
- How Might Sleeping Pills Damage the Brain’s Waste Clearance System?
- Who Is Most at Risk From Long-Term Sleep Medication Use?
- What Are Safer Alternatives to Sleeping Pills for Older Adults?
- The Correlation Problem — Do Sleeping Pills Cause Dementia, or Do They Signal It?
- What the Numbers Mean at a Population Level
- Where the Research Is Heading
- Conclusion
- Frequently Asked Questions
What Do Studies Say About Sleeping Pills and Dementia Risk?
The evidence linking sleeping pills to dementia has been building for years, but three studies stand out. The UCSF study, published in January 2023 in the Journal of Alzheimer’s Disease, followed 3,068 older adults with an average age of 74 over approximately nine years. None had dementia at the start. By the end of the study period, roughly 20% had developed dementia. Among white participants, frequent sleep medication use was associated with a 79% higher risk. The study included both white and Black participants — 58% and 42% respectively — and notably, Black participants did not show the same elevated risk, though they were far less likely to be frequent users of prescription sleep medications in the first place.
A separate nationally representative study published in 2021 and available through PubMed Central found that sleep medication use was associated with a 48% greater risk of dementia in fully adjusted analyses. Then, in October 2025, The Lancet published research examining three classes of sleep medications and their links to falls, cognitive impairment, and early death in older adults. The modeling in that study estimated that avoiding sleep medications would reduce the lifetime incidence of falls by 8.5%, reduce cognitive impairment by 2.1%, increase life expectancy by 1.3 months on average, and save approximately $6,600 per person — translating to roughly $101 billion across the U.S. population. These are not fringe findings. They come from large, peer-reviewed studies published in respected journals, and the consistency of the association across different populations and methodologies makes them difficult to dismiss outright.
How Might Sleeping Pills Damage the Brain’s Waste Clearance System?
For years, the link between sleeping pills and dementia remained purely statistical — researchers could see the correlation but couldn’t explain the mechanism. That changed in January 2025, when a study published in the journal Cell by researchers at the University of Rochester and the University of Copenhagen offered a compelling biological explanation. They discovered that norepinephrine-driven oscillations during non-REM sleep power the glymphatic system, the brain’s waste-clearance network responsible for flushing out amyloid and tau proteins linked to neurodegeneration. Here is the critical finding: zolpidem, the active ingredient in Ambien and one of the most widely prescribed sleep aids in the world, effectively induced sleep but suppressed the norepinephrine oscillations that drive glymphatic flow. In other words, the drug put people to sleep, but it shut down the very process that makes sleep restorative for the brain. The brain’s ability to clear toxic waste proteins was impaired.
This suggests that drug-induced sleep may not provide the same neurological benefits as natural sleep — a distinction most people never consider when reaching for a pill. However, this does not mean all sleep medications work the same way. The Cell study specifically examined zolpidem, and it would be premature to assume every sedative or sleep aid suppresses glymphatic function identically. Different drug classes act on different receptors and neurotransmitter systems. That said, the finding is a serious warning sign, because zolpidem is among the most commonly used sleep medications worldwide. A separate retrospective study in Taiwan found that zolpidem use may increase dementia risk in elderly patients, especially those with hypertension, diabetes, or stroke history — suggesting that people who already have vascular risk factors may be particularly vulnerable.
Who Is Most at Risk From Long-Term Sleep Medication Use?
Not everyone faces the same level of risk. The UCSF study made this clear: among the 3,068 participants, the elevated dementia risk was concentrated among white adults who used sleep medications frequently. Black participants did not show the same association, though the researchers cautioned that this finding may partly reflect lower rates of prescription sleep medication use among Black older adults rather than a true biological difference. The study also found that occasional use — taking a sleeping pill now and then — showed no increased dementia risk in either group. Age and existing health conditions also appear to matter. The Taiwanese retrospective study on zolpidem found that elderly patients with hypertension, diabetes, or a history of stroke faced a higher risk of dementia when using the drug.
This makes intuitive sense: if sleeping pills impair the brain’s waste clearance system, people whose brains are already under stress from vascular disease may be less able to compensate. Consider, for example, a 72-year-old with Type 2 diabetes who has been taking Ambien nightly for five years. According to the available research, that person sits in a higher-risk category than a healthy 55-year-old who takes a sleeping pill once or twice a month before a flight. The Lancet study from October 2025 added another dimension to the risk profile: falls. Older adults on sleep medications were significantly more likely to fall, and falls in the elderly often trigger a cascade of hospitalization, reduced mobility, and accelerated cognitive decline. The modeling suggested that eliminating sleep medication use would reduce lifetime fall incidence by 8.5% — a substantial figure when you consider that a hip fracture in a person over 75 can be a life-altering event.
What Are Safer Alternatives to Sleeping Pills for Older Adults?
The most consistently recommended alternative across the medical literature is cognitive behavioral therapy for insomnia, known as CBT-I. Unlike sleeping pills, CBT-I addresses the underlying behavioral and psychological patterns that cause insomnia rather than chemically overriding them. It typically involves sleep restriction, stimulus control, relaxation training, and restructuring the anxious thoughts that keep people awake. Multiple studies have found CBT-I to be as effective as medication in the short term and more effective in the long term, because the skills learned persist after treatment ends. The tradeoff, of course, is effort and access. A sleeping pill works the first night you take it.
CBT-I requires several weeks of consistent practice and ideally a trained therapist, though digital CBT-I programs have become widely available and show promising results. For someone in the grip of severe insomnia — unable to function at work, emotionally frayed, desperate for rest — the appeal of an immediate pharmacological solution is understandable. The research does not suggest that a person should suffer through dangerous levels of sleep deprivation rather than ever take a pill. But it does suggest that sleep medications should be treated as a short-term bridge, not a long-term strategy, particularly for anyone over 65. Other non-pharmacological approaches include maintaining a consistent sleep schedule, limiting caffeine after noon, keeping the bedroom cool and dark, and avoiding screens in the hour before bed. These sound simple, and they are, but their cumulative effect on sleep quality is well-documented and carries zero dementia risk.
The Correlation Problem — Do Sleeping Pills Cause Dementia, or Do They Signal It?
One of the most important caveats in all of this research is the difficulty of separating cause from effect. Sleep disturbances — difficulty falling asleep, waking frequently during the night, changes in sleep architecture — are well-established early symptoms of neurodegenerative diseases, including Alzheimer’s. It is entirely possible that some portion of the association between sleeping pills and dementia reflects people who are already in the earliest, pre-diagnostic stages of the disease turning to medication because their sleep has deteriorated. This is not a trivial objection. The UCSF study attempted to account for it by excluding participants who had dementia at baseline and adjusting for known confounders, but no observational study can fully eliminate reverse causation.
The 2021 nationally representative study faced similar limitations. Even the Lancet modeling study relied on observational data that cannot prove causality. What strengthens the case for a causal link, however, is the Cell study from January 2025. By identifying a specific biological mechanism — zolpidem’s suppression of the norepinephrine oscillations that drive glymphatic waste clearance — researchers moved beyond correlation into plausible causation. If a drug demonstrably impairs the brain’s ability to clear amyloid and tau proteins, it is reasonable to hypothesize that chronic use could contribute to the accumulation of those proteins over time. This does not settle the debate, but it shifts the balance of evidence.
What the Numbers Mean at a Population Level
The Lancet study’s population-level estimates are striking and worth sitting with. Across the entire U.S. older adult population, the researchers estimated that eliminating sleep medication use would save approximately $101 billion in healthcare costs and add 1.7 million life-years.
At the individual level, that translates to about $6,600 in savings per person and 1.3 additional months of life expectancy. These are not dramatic numbers for any single person, but they represent an enormous public health burden when aggregated. For context, 1.7 million life-years is roughly equivalent to preventing several thousand premature deaths per year — a figure that would justify significant public health intervention in almost any other context.
Where the Research Is Heading
The discovery of the glymphatic system’s role in sleep and neurodegeneration has opened a new chapter in this field. Researchers are now investigating whether certain classes of sleep medications spare the norepinephrine oscillations that drive brain waste clearance, which could eventually lead to safer pharmacological options for people who genuinely need help sleeping.
There is also growing interest in whether short-term or intermittent use of sleep medications poses any glymphatic risk at all, or whether the damage is primarily associated with chronic, nightly use over years. For now, the practical takeaway is straightforward: if you are over 65 and taking sleeping pills regularly, it is worth having a conversation with your doctor about tapering off and exploring CBT-I or other behavioral strategies. The evidence is not yet definitive enough to say sleeping pills cause dementia, but it is strong enough — and the potential consequences serious enough — that continuing to use them without considering alternatives is a risk most people would want to understand.
Conclusion
The research linking sleeping pills to dementia risk has grown more concerning with each passing year. From the UCSF study’s finding of a 79% increased risk among frequent users, to the 2025 Cell study revealing how zolpidem disrupts the brain’s waste clearance system, to the Lancet’s population-level modeling showing billions of dollars in avoidable healthcare costs, the pattern is consistent. Frequent, long-term use of sleep medications in older adults is associated with worse cognitive outcomes, more falls, and shorter lives. The most important thing to remember is that occasional use has not been linked to elevated risk, and no one should abruptly stop a prescribed medication without medical guidance.
But for the millions of older adults who take sleeping pills every night as a matter of routine, these findings are a clear signal to explore alternatives. CBT-I remains the gold-standard recommendation, and a growing body of evidence suggests it is at least as effective as medication without the associated risks. Talk to your doctor. The goal is not to suffer through sleepless nights — it is to find ways to sleep well that do not come at the expense of long-term brain health.
Frequently Asked Questions
Do all sleeping pills increase dementia risk?
The research has examined several classes of sleep medications, and the Lancet study from October 2025 linked three different classes to increased risk of falls, cognitive impairment, and early death. However, not all sleep medications have been studied equally. Zolpidem (Ambien) has the most evidence against it, including a biological mechanism showing it suppresses the brain’s waste clearance system. The risk appears to be associated with frequent, long-term use rather than the occasional pill.
Is it safe to take a sleeping pill once in a while?
Based on the available evidence, occasional use has not been linked to increased dementia risk. The UCSF study specifically found that only frequent use — “often” or “almost always” — was associated with the 79% higher risk figure. Taking a sleeping pill before a long flight or during a particularly stressful week is a very different scenario from nightly use over months or years.
Should I stop taking my sleeping pills immediately?
No. Abruptly stopping sleep medications can cause rebound insomnia, anxiety, and in some cases withdrawal symptoms. If you are concerned about your use, talk to your doctor about a gradual tapering plan and discuss alternatives like cognitive behavioral therapy for insomnia. Never discontinue a prescribed medication without medical supervision.
What is CBT-I, and does it actually work?
Cognitive behavioral therapy for insomnia is a structured program that helps you change the thoughts and behaviors that prevent good sleep. It typically involves sleep restriction, stimulus control, and relaxation techniques. Multiple studies have found it to be as effective as sleep medication in the short term and more effective over time, because the benefits persist after treatment ends. It is available through therapists and increasingly through digital programs.
Why did the UCSF study find different results for Black and white participants?
The study found that white participants who frequently used sleep medications had a 79% higher dementia risk, while Black participants did not show the same association. The researchers noted that Black participants were far less likely to be frequent users of prescription sleep medications, which may have limited the study’s ability to detect an effect in that group. The difference may also reflect disparities in the types of medications prescribed or other unmeasured factors.
Does poor sleep itself increase dementia risk?
Yes. Chronic poor sleep is independently associated with higher dementia risk, which is part of what makes this issue so complex. Sleep is when the brain clears toxic waste proteins, so both inadequate sleep and medications that disrupt that clearance process may contribute to neurodegeneration. The challenge is finding ways to improve sleep quality without relying on drugs that may undermine the brain’s restorative processes.
